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Human amniotic fluid  has been shown to  contain  a 
protein that binds  insulin-like  growth  factor I and I1 
(IGF-I and IGF-11). Partially purified  preparations of 
this protein  have been reported  to  inhibit  the biologic 
actions of the IGFs. In these studies  our  laboratory  has 
used a modified purification  procedure to obtain a ho- 
mogeneous preparation of this  protein as determined 
by polyacrylamide gel  electrophoresis  and amino acid 
sequence analysis. During purification the ion ex- 
change chromatography  step  resulted in two  peaks of 
material  with IGF binding  activity  termed  peaks  B  and 
C. Each peak  was  purified  separately  to homogeneity. 
Both peaks were estimated to be 31,000 daltons by 
polyacrylamide gel electrophoresis and their amino 
acid compositions were  nearly identical. Amino acid 
sequence analysis showed that both peaks had identical 
N-terminal sequences through the first 28 residues. 
Neither  protein  had  detectable  carbohydrate  side 
chains  and each had  a  similar  affinity  for radiolabeled 
IGF-I (1.7-2.2 X 10” liters/mol). In contrast, these 
two  forms had marked  differences in bioactivity. Con- 
centrations of peak C material between 2 and 20 ng/ 
ml inhibited IGF-I stimulation of [3H]thymidine incor- 
poration into smooth muscle cell DNA. In contrast, 
when peak B (100 ng/ml) was incubated with IGF-I 
there was a 4.4-fold enhancement of stimulation of 
DNA synthesis. Additionally, pure peak  B  was shown 
to adhere to cell surfaces, whereas peak C was not 
adherent. The non-adherent peak C inhibited IGF-I 
binding to its receptor and to adherent peak B. We 
conclude that human amniotic fluid  contains  two  forms 
of IGF binding  protein that have  very  similar physio- 
chemical characteristics  but  markedly  different biolo- 
gic actions, Since both have similar if not identical 
amino acid compositions, N-terminal sequences, and do 
not contain  carbohydrate, we conclude that they  differ 
in some other as yet undefined post-translational mod- 
ification. 
Somatomedin C, also termed insulin-like growth factor I 
(IGF-I),* is a peptide growth factor that stimulates growth in 
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many types of cultured cells (1, 2). Although many cell types 
and tissues secrete IGF-I (3, 4),  it is uncertain whether this 
locally produced IGF-I stimulates growth in the regional 
microenvironment or is transported  through blood to stimu- 
late growth at sites distant from its site of synthesis (5). 
Compounding this difficulty in understanding the mecha- 
nisms by which the IGFs stimulate growth is the observation 
that IGF-I and IGF-I1 circulate in blood bound to binding 
proteins (6, 7). Extracellular fluids (8) and cell culture  super- 
atants (9) also contain  IGF binding proteins, suggesting that 
the IGFs are present in a bound form in the extracellular 
microenvironment. Since  these  proteins bind IGF-I and IGF- 
I1 they  are believed to inactivate these substances (10). There 
are two major classes of IGF binding proteins. One is a 
glycoprotein (-53 kDa) that is synthesized by hepatocytes 
(11) and in plasma forms a  stable 150-kDa complex with IGF- 
I (12). This protein is growth hormone-dependent (13). In 
contrast, extracellular fluids such as ascites (14), spinal (15), 
follicular (16), and amniotic (17) contain a protein whose 
molecular size has been estimated to be between 30 and 38 
kDa and is not growth hormone-dependent. Recently our 
laboratory has shown that human fibroblasts secrete this 
protein  and that  it adheres to  the fibroblast surface (18). The 
surface-adherent protein directly alters IGF-I binding such 
that  the binding of radiolabeled IGF-I is paradoxically in- 
creased when low concentrations of unlabeled IGF-I  are added 
(18). Since this form of binding protein is present  in many 
types of extracellular fluids it  has the potential to  alter  the 
cellular responses to IGF-I.  These  studies were undertaken to 
determine the physiochemical properties of a  pure  preparation 
of the human amniotic fluid derived IGF binding protein  and 
to determine whether it could alter  the biologic effects of IGF- 
I. 
EXPERIMENTAL PROCEDURES 
Materials-Human amniotic fluid was obtained from Dr. A. J. 
D’Ercole (University of North Carolina) from discarded amniocen- 
tesis samples. Ammonium sulfate and sodium chloride were pur- 
chased from EM Sciences, Cherry Hill, NJ. Rabbit y-globulin, DEAE- 
cellulose, ammonium persulfate, sodium thiocyanate, Sephadex G- 
100, polyethylene glycol (Mr 8,000) and ammonium carbonate were 
purchased from Sigma. Phenyl-Sepharose CL-4B was purchased from 
Pharmacia  LKB Biotechnology Inc., and  the C-4 reverse-phase 
HPLC column from Vydac, Hesperia, CA. Acetonitrile, Gel Code 
silver stain  kit, and trifluoroacetic acid were purchased from Pierce 
Chemical Co. Tris,  SDS, and  TEMED were obtained from Bethesda 
Research Laboratories. Glycine, bromphenol blue, Servalyt isoelectric 
focusing precotes, and glycerol  were obtained from Serva, Heidelberg, 
West Germany. Tissue culture plates were purchased from Falcon 
Labware Division, Becton Dickinson, Oxnard, CA. 
Protein Purification-Crude amniotic fluid (230 ml) was equili- 
brated with 45 g of ammonium sulfate (33% saturation), stirred for 
30 min at 4 “C and centrifuged at 27,000 X g for 20 min. The pellet 
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was discarded and  the  supernatant was adjusted to 50% saturation 
with ammonium sulfate and stirred for 30 min and  the centrifugation 
step repeated. This pellet (33-50%) was resuspended in 50  ml of 0.05 
M Tris,  pH 7.4, and 1.2 ml of saturated ammonium sulfate added to 
achieve a final concentration of  0.14 M. This solution was applied to 
a phenyl-Sepharose column (2.2 X 15.0 cm) that had been previously 
equilibrated with 0.05 M Tris, pH 7.4, in 10% ammonium sulfate. 
Following sample loading, the column was washed with the loading 
buffer until the absorbance (280 nm) returned to base line. The 
column was eluted with step gradients of the following composition: 
1) 0.05 M Tris, 0.5 M sodium thiocyanate, pH 7.4; 2) 0.05 M Tris, pH 
7.4; 3) 0.02 M Tris,  pH 9.0; and 4) HzO. Each fraction was assayed 
for IGF-I binding activity (see below). The active fractions were 
pooled, the  pH was adjusted to 7.2 with 1.0 M acetic acid, and  the 
solution was applied directly to a DEAE-cellulose column that had 
been equilibrated with 0.01 M (NH4)&03,0.01 M NaCl, pH 7.2. After 
sample application the column was washed extensively with the 
equilibration buffer until the absorbance (280 nm) returned to base 
line. The column was eluted with step salt gradients containing 0.1, 
0.25, and 1.0 M NaCl in the equilibrium buffer. The fractions were 
assayed for IGF binding as described. Greater than 80% of the activity 
eluted with 100 or  250 mM NaCl. These two peaks, termed  B and C, 
were purified separately. 1.5 ml of the peak B pool was applied to a 
C-4 Vydac reverse-phase HPLC column (0.46 X 25 cm) that had been 
equilibrated with 0.04% trifluoroacetic acid. The mobile phase was 
run isocratically for 5 min and  then a  linear gradient from 0 to 100% 
acetonitrile plus 0.04% trifluoroacetic acid was run over 25 min. The 
IGF binding protein activity of each fraction was determined and  the 
active fractions were  pooled and stored at -20  "C. 
Pool C from the ion exchange column was first purified by Seph- 
adex G-100 column chromatography. 10 ml of pool C was applied to 
a 2.2 X 90 cm column that had been equilibrated with 0.01 (NH4)2C03, 
0.05 M NaCl, pH 7.2. The column was eluted using a flow rate of 30 
ml/h and approximately 9-ml fractions were collected. The IGF-I 
binding activity was determined (as described below). The active 
fractions were  pooled and applied directly to  the reverse-phase C-4 
column. The elution conditions that were identical to those stated 
previously were  used. 
Iz5f-IGF-I Binding Capacity-IGF-I binding activity of the column 
fractions was determined as follows using a polyethylene glycol pre- 
cipitation method (18). 10 pl of each fraction was incubated with lZ6I- 
IGF-I (340  pCi/pg) (final concentration of  0.27 ng/ml) for 60 min at 
22 "C in 0.1 HEPES, 0.1% BSA, 0.01% Triton X-100, 44 mM Na- 
HCOa, 0.02% NaN3, pH 6.0 (250 pl total volume). The IGF-I was 
iodinated by a published method (19). Bound and free '2SI-IGF-I were 
separated by adding 250 p1 of 1% human y-globulin and 500 p1 of 
25% polyethylene glycol (Mr 8000) (final concentration of 12.5%). 
The mixture was centrifuged at 1000 X g for 15 min. The pellet was 
washed with 1 ml of 6.25% polyethylene glycol and  the final pellet 
counted in a y spectrometer. Nonspecific binding was determined by 
measuring the amount of "'I-IGF-I that could  be precipitated in the 
presence of 1.0 pg/ml unlabeled IGF-I. It was consistently <5% and 
was subtracted from the  total radioactivity that was precipitated. To 
determine overall recovery, each pool of active fractions was reassayed 
at  several concentrations and  the binding capacity of the pools was 
compared to a  human amniotic fluid standard. The  data were used to 
assign a unit value to each pool. One unit was the quantity of the 
binding protein  in human amniotic fluid necessary to achieve half- 
maximal IGF-I binding in  that assay. This corresponds to 250-300 
pg of pure IGF binding protein which binds approximately 83-100  pg 
To determine the binding capacity and affinity of the pure IGF 
binding protein for IGF-I, radiolabeled IGF-I (340 pCi/pg; 0.27 ng/ 
ml) was incubated with 14 ng/ml each binding protein and Increasing 
concentrations of unlabeled IGF-I in 0.25 ml of 0.03 M NaHzP04, 
0.01 M EDTA, 0.05% Tween 20, pH 7.4. After 48 h at 4 "C the bound 
and free "'I-IGF-I were separated by adding a 1:250 dilution of a 
rabbit  anti-binding  protein antibody which had been prepared using 
a mixture of peaks B and C binding proteins and the incubation 
continued for 24 h. At that time 8 pl of goat anti-rabbit serum was 
added and  the mixture incubated for 1 h at 22 "C. 2 pl of normal 
rabbit serum was added and  the mixture incubated for an additional 
1 h. The bound and free growth factors were separated by centrifu- 
gation at 8000 X g for 10 min. 
Physiochemical Analysis-The purity of both peaks B and C was 
determined by SDS-polyacrylamide gel electrophoresis. The running 
gel  was 12% acrylamide containing 0.375 M Tris, 0.1% SDS,  pH 8.8, 
and the stacking gel  was 4% acrylamide in 0.125 M Tris, 0.1% SDS, 
of IGF-I. 
pH 6.8. 0.1-10 pg of sample was diluted to 75 pl in 0.1 M Tris, pH 
6.8, 10% glycerol, 5% SDS, and 0.02% bromphenol blue and the 
samples were heated to 100 "C for 5 min. The supernatants were 
clarified, the gel lanes loaded, and  the proteins  separated for 14  h a t  
65 V. Silver staining was performed using Gel code silver staining 
kit. The lower limit of detection of the technique was 25 ng as 
determined using known protein  standards. 
Amino Acid  Composition and Sequence Analysis-Amino acid 
analysis was performed by the PICO-TAG method (19), described 
briefly as follows. 500 ng of each protein was hydrolyzed in an 
evacuated, sealed vessel containing fumes of 6 N HCl and 0.1% phenol 
at 150 "C for 1 h. The hydrolysate was derivatized with phenylisothi- 
ocyanate to generate the phenylthiocarbamyl derivative of each amino 
acid and  the mixture applied to a reverse-phase HPLC column (20). 
To determine the amino acid sequence of peak B, an aliquot (12 
pg)  was extensively reduced and alkylated to modify cysteine residues 
to  their more stable carboxymethyl derivatives. Briefly, the aliquot 
was reduced in the presence of 5 M guanidine HCl at  pH 8.6 for 1 h 
at 37 "C. The reducing agent was 0.05 M dithiothreitol. Alkylation 
was performed at  room temperature by adding iodoacetic acid to 0.11 
M and incubating the mixture in the dark for 1 h. The alkylated 
protein was separated from reagents by rechromatography using 
HPLC ((2-4 column) as previously described. Guanidine and other 
reagents are not retained by this reverse-phase column. 6 pg  of eluted, 
modified protein was placed on a polybrene (21)-treated glass fiber 
filter in  an Applied Biosystems model 470A gas phase sequenator and 
subjected to repetitive Edman degradation. Phenylthiohydantoin  de- 
obtained using a Waters gradient HPLC  and a NOVA-PAK C-18 
rivatives were identified by comparing their  HPLC elution profiles 
reverse phase column with the elution profiles of known mixtures of 
phenylthiohydantoin derivatives. 
Determination of Carbohydrate Content-To determine whether 
either peak B or  C  contained carbohydrate, 20.0  pg  of each peak was 
loaded on a 12% SDS-polyacrylamide gel and separated for 14 h as 
described previously. Fetuin was run  in parallel as a  standard. The 
gel was fixed with 10% acetic acid/25% isopropyl alcohol. The gel 
was then washed sequentially with 1) 0.5% periodic acid, 2) 0.5% 
sodium arsenite/5% acetic acid, 3) 0.1% sodium arsenite/5% acetic 
acid, 4) 5% acetic acid, 5) Schiffs reagent (overnight), and 6) 0.6% 
sodium metabisulfite/O.Ol M HCl. 
To further  determine whether either peak B  or peak C contained 
carbohydrate, 1.5 pg of each protein was applied to a concanavalin 
A-Sepharose column that  had been equilibrated in 0.02 Tris,  pH 7.5, 
2 mM CaClz, and 2 mM MgClZ. The column was  slowly loaded over 2 
h and allowed to stand for 45 min at 22  'C. The column was further 
washed with 20 ml of starting buffer and  then eluted with 10 ml of 
0.02 M Tris,  pH 7.5, containing 0.5 M a-methyl-D-mannoside and 0.1 
M NaC1. After standing for 1 h, the column was reeluted with the 
same buffer. The fractions were tested for IGF binding activity as 
described previously. 
Determination of PHIThymidine Incorporation into DNA-The 
biologic activity of pure peak B and C material was assessed by 
determining the capacity of each to stimulate DNA synthesis in 
porcine aortic smooth muscle cells. The smooth muscle cells were 
isolated and maintained  in stock cultures using previously described 
methods (22). The cells from stock cultures were subcultured in 
microtest 96-well plates (Falcon 3004) by plating at 8000  cells/well 
in DMEM (GIBCO) containing 10% fetal bovine serum. 5 days after 
plating, the wells were washed once with serum-free DMEM, and 
then test factors were added to each well in 0.2 ml of DMEM 
supplemented with 1% platelet-poor plasma (PPP) and 0.5 pCi of 
[3H]thymidine. PPP was prepared by a previously described method 
(23). After 36 h of incubation the wells were washed twice with 
Ringer's bicarbonate and twice with 5% trichloroacetic acid (4 "C), 
and  the DNA  was extracted twice with 0.4 ml of 0.3 N NaOH. [3H] 
Thymidine incorporation was determined by liquid scintillation 
counting. 
Isoelectric Focusing-To determine their isoelectric points, 2.5  pg 
of peak B and C  proteins were loaded onto precast isoelectric focusing 
plates, pH 3-10 (Servalyt Precotes). 20 pg of known standards was 
run  in  a parallel lane. The prot,eins were electrofocused for 1.5 h at 
200 V, and  then for 1.5 h at 1000 volts. The gel was divided into two 
sections and one half  was  fixed in 10% trichloroacetic acid and  then 
stained with Serva Blue according to directions. The other half was 
cut into 0.5-cm sections and eluted with 0.04% trifluoroacetic acid. 
The eluates were analyzed for IGF binding activity as described 
previously. 
Determination of lZ51-IGF-I and "'I-IGF Binding Protein Binding 
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to Cell Monolayers and Affinity Labeling-Prior to conducting the 
binding experiments, pig smooth muscle cells were grown to con- 
fluency in 24-well plates (Falcon 3003) and washed three times in 
PBS. The cultures were then incubated for 14 h at 37 "C with  varying 
concentrations of pure peak B or C in  0.5  ml of minimum essential 
medium. The plates were  washed  twice  with PBS  and  fresh  peak B 
or C was added with '"I-IGF-I (0.27 ng) to 0.25 ml of minimum 
essential medium containing 20 mM HEPES and  0.1% BSA.  After 2 
h at 4 'C the media  was aspirated, the monolayers  were  washed  four 
times in PBS, and the cell-associated  lZ5I-IGF-I was determined as 
previously  described (18). Nonspecific  binding  was determined in the 
presence of  500 ng/ml  unlabeled  IGF-I  and that value  was subtracted 
for  all points. The IGF  binding  protein  was  iodinated  using a modi- 
fication of the method that was  used to prepare  '261-IGF-I (19). 0.5 
pCi  of Na-lZ6I was  added to 0.1  ml of 0.5 M NaP04, pH  7.5, containing 
2.0-4.0  pg  of protein.  Chloramine T (50 p ~ )  was added.  After 3 min, 
the percentage  precipitability  in 20% trichloroacetic  acid was deter- 
mined and further chloramine T was  added until the iodinated  protein 
was  70% precipitable. The mixture  was  purified  by  Sephadex  G-100 
chromatography. The relative specific activity of peaks B and C was 
81 and 152  NCi/pg,  respectively.  Direct  measurements  of  I2T-binding 
protein  binding were determined  as  described  for  "'I-IGF-I  except 
that the concentration of radiolabeled protein in the incubation 
mixture was  2.0  ng/ml. 
Affinity labeling  was  performed  using a previously  described 
method (18). The cells were grown to confluency in 35-mm dishes 
(Falcon  3002). The preincubation step with  peaks B and C and the 
binding  reaction  were carried  out as described  above  except that  a 1.0 
ml incubation volume and 2.0  ng/ml of 'T-IGF-1 was used.  Following 
the binding  experiment, the monolayers  were  washed and  disuccin- 
imidyl suberate was  added in a final  concentration of 0.1 mM in  1.0 
ml of binding  buffer  without BSA (18). After 10 min at 22 "C,  the 
reaction  was  quenched  with  10 mM Tris, pH  7.0. The cell  monolayers 
were extracted  with 1% SDS  and  boiled  for 5 min,  and the supernatant 
was clarified by centrifugation at 10,000 X g for 3 min. The super- 
natants were loaded on to 10% SDS-polyacrylamide gels and the 
proteins  separated as described  previously (18). The gels  were  fixed 
with 10% acetic  acid and 30% methanol, washed,  dried, and exposed 
to Kodak X-0-mat film. 
RESULTS 
Ammonium sulfate  precipitation of 230 ml of amniotic fluid 
resulted  in recovery of IGF  binding  activity  in  both  the  33 
and 50% pellets. The majority of the  activity was present  in 
the 50% pellet and  this was chosen for further  purification. 
During phenyl-Sepharose chromatography, the majority of 
contaminating  protein  eluted  with 0.5 M sodium thiocyanate 
as  described previously  (24) (Fig. 1). The  peak  containing  the 
IGF binding  protein  eluted  with 0.02 M Tris,  pH 9.0, and  had 
been purified 9.5-fold (Table I). Further  purification by ion 
exchange  chromatography  resulted  in  separation of two major 
peaks of binding  activity which eluted at 100 and 250 mM salt 
(Fig. 2). These peaks (termed peaks B and C) were pooled 
and  further purified separately.  Peak C material was  purified 
by Sephadex G-100 chromatography. The binding protein 
activity eluted over a broad peak but was separated from 
larger molecular  weight contaminants (Fig. 3). 60 pg of G-100 
purified material was further purified by reverse-phase HPLC 
using a C-4 column. The active  material was eluted  as a single 
peak a t  50% acetonitrile and was stable during storage at 
-20 "C for periods of up to 3 months (Fig. 4A). Peak B was 
purified by reverse-phase HPLC and  this  step  resulted  in a 
9.4-fold purification (Fig. 4B). 
To  determine  the  purity,  estimate  the molecular size of each 
protein,  and  determine  the efficacy of each  separation  method 
in removing contaminants,  the  protein at each  stage of puri- 
fication of peak C was  subjected to polyacrylamide gel elec- 
trophoresis  under  nonreducing  conditions followed by silver 
staining (Fig. 5 ) .  The pure product has a molecular mass 
estimate of 31  kDa  and  appears  as a single band  after  the 
final  purification  step (panel F ) .  The phenyl-Sepharose  step 
appeared  to be the most  effective  procedure  for  removing the 
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FIG. 1. Phenyl-Sepharose fractionation of the 33-60% am- 
monium sulfate pellet obtained from human amniotic fluid. 
The pellet  was  dissolved  in  0.05 M Tris, 0.14 M (NH&SO*,  pH  7.4, 
and  applied to the column that had  been preequilibrated  with 0.05 M 
Tris, pH 7.4, containing 10% w/v ammonium sulfate. Following 
sample  loading, the column  was  rinsed  with equilibrating  buffer  and 
eluted  with the following  buffers as  indicated by arrows: A ,  0.05 M 
Tris, 0.5 M sodium thiocyanate, pH 7.4; B, 0.05 M Tris, pH 7.4; C, 
0.02 M Tris, pH  9.0; D, deionized  water.  Heavy  durk  line represents 
the absorbance at 280 mM, bars depict the percent maximum IGF-I 
binding activity. Fractions (83-98), pooled for further purification, 
are indicated (w). 
contaminating  proteins. Comparison of pure  peaks B and C 
on  SDS-PAGE showed that  they  both  had  identical RF values 
(Fig. 6).  The molecular mass estimates were 31 kDa under 
nonreducing  conditions  but  the  estimate of each  increased to 
36 kDa if the  proteins were  reduced prior  to  electrophoresis 
(data  not  shown).  This gel was  deliberately  overloaded  (10 pg 
of each protein)  to  detect  contaminants.  The  69-kDa  band  is 
a dimer.  Isoelectric  focusing of each  protein showed peak B 
had a PI value of  5.4, whereas peak C was 5.3 (Fig. 6). 
When  the  amino acid compositions of peaks B and C were 
determined  nearly  identical  amino acid ratios were obtained 
(Table 11). The  actual composition is  in close agreement  with 
previously  published data  (24).  Reduction  and  alkylation of 
peak B and  peak C followed by N-terminal sequence deter- 
mination  is shown in  Table 111. The result for amino  acids 1- 
10 agrees with that published by two groups (24, 25) and 
further  confirms  that  the  protein  that was purified was the 
IGF binding protein. Positions 11 and 12 differ from the 
published sequence for placental protein 12 (25). However, 
these differences are only one base substitution  in  the codons 
coding  for each  amino acid. This suggests that  the  placental 
protein 12 sequence may be  distinct  and  that  the difference 
is not  artifactual.  When  compared  with  the sequence of the 
rat  IGF  binding  protein,  the  cysteine  positions a t  5,8, and 16 
appear  to  be conserved. Both  proteins were stable  after  heat- 
ing to 100 "C for 10  min  and were stable  to  pH 2.5. 
Further physiochemical analysis was performed  to  deter- 
mine whether carbohydrate side chains were present. Al- 
though  one  group  had  reported  that  the  protein  contained  no 
carbohydrate  (24) we noted  that  pure  preparations of peak B 
or C adhered  to  concanavalin A. When 2 pg of each  protein 
was applied to  the  concanavalin A column, 51% of peak C 
adhered and was eluted with 0.5 M a-methyl-D-mannoside, 
whereas  only 24%  of peak B was adherent.  When  each peak 
was treated with N-glycanase  prior  to  concanavalin A chro- 
matography,  no  change  in  the  elution  pattern was noted  (data 
not  shown).  This suggested that  the  binding  to  concanavalin 
A was nonspecific. This result was confirmed by SDS gel 
electrophoresis of 20 pg of either  peak B or C followed by 
staining with  Schiff s base,  which  showed that  neither  protein 
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TABLE I 
Recovery of IGF binding  protein  duringpurification 
Purification  steps Total  Total protein  activitf Specific  activity Recovery Purification 
w units unitslmg % -fold 
Amniotic fluid 1,242' 92,000 7.4 x 10' 100 1 
Ammonium sulfate  frac- 186.5' 62,500 
tionation (33-50% 3.35 x lo2 68 4.5 
saturation) 
Phenyl-Sepharose 18.12' 55,000 3.04 X 103 60 41.0 
DEAE-Cellulose 5.15'  7.13" 17,600  29,300 3.4 X lo3 4.1 X lo3 19 32  46  35 
Sephadex G-100 3.92'  27,800  7.1 X lo3 30  96 
B  C  B  C  B  C B C B C 
HPLC C-4 0.545d  0.992d  17,600  27,80  3.2 X lo4 2.8 X lo4 19  30  432  37  
a One unit of activity is the quantity of fluid necessary to stimulate one-half of maximal binding activity in the 
IGF-I binding capacity assay. 
Based on binding capacity assay protein determination. 
Based on amino acid composition. 
e Based on absorbance at  280 mM. 
FRACTION NUMBER 
FIG. 2. DEAE-cellulose chromatography of partially puri- 
fied IGF-I binding activity. Fifty-five ml of the IGF-I binding 
protein activity obtained from the phenyl-Sepharose chromatography 
(fractions 83-98)  was acidified to pH 7.2 with acetic acid and applied 
to a DEAE-cellulose column previously equilibrated with 0.01 M 
(NH4),C03, 0.01 M NaCl, pH 7.2. After sample loading, the column 
was rinsed with equilibrating buffer and eluted stepwise with 0.1, 
0.25, and 1.0 M NaCl, all containing 0.01 M (NH&C03, pH 7.2, as 
indicated. Absorbance at 280 mM (-1 and percent maximum IGF- 
I binding activity (M) are indicated. Fractions pool for further 
purification are depicted as pools B  and  C (H); fractions 6-14 and 
18-22, respectively. 
contained detectable carbohydrate. Based on the staining 
intensity of a  fetuin  standard it could  be determined that each 
protein contained less than 0.5% of its weight as carbohydrate. 
To determine the affinity of each protein for IGF-I, increas- 
ing concentrations of unlabeled IGF-I  and  lZ5I-IGF were in- 
cubated with peak B or C and  the bound complexes immu- 
noprecipitated. The  data were analyzed using Scatchard plots. 
Both proteins have binding characteristics that are  consistent 
with either  a two-site model with high and low affinity binding 
sites or a one-site model with negative cooperativity. The 
relative affinities of the high affinity sites of the peak B and 
C proteins are very similar: 1.7 and 2.2 X 10" liters/mol, 
respectively (Fig. 7). 
In  spite of their physiochemical similarity, the peak B and 
C materials were found to have markedly distinct biologic 
properties. Pure peak B material greatly potentiated the 
smooth muscle  cell  DNA synthesis response to IGF-I,  but had 
no effect alone or with an equivalent concentration of human 
insulin (Fig. 8). In contrast, peak C material inhibited basal 
and  IGF-I-stimulated  [3H]thymidine incorporation and  mark- 
edly inhibited the response to peak B plus IGF-I (Fig. 8). This 
effect was detectable at concentrations  as low as 2.0 ng/ml 
peak C and was maximal at 20 ng/ml. To exclude the possi- 
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FIG. 3. Sephadex G-100 chromatography of DEAE-pool C 
IGF-I binding activity. Ten ml  of DEAE-pool C was fractionated 
on a Sephadex G-100 column (22 mm X 90 cm). The column was 
equilibrated and eluted with 0.01 M (NH1)2C03, pH 7.1, containing 
0.05 M NaCl. Fractions of approximately 9 ml  were collected. IGF-I 
binding activity is indicated (n) as is absorbance at 280 nm (-1. 
H indicates region of pooling for further purification. Catalase 
(200,000), BSA (69,000), myoglobin (18,500), and phenol red (346) 
were used as molecular weight standards. 
due to changes in  the cell  cycle kinetics, the  rate of entry  into 
DNA synthesis of smooth muscle cells was determined  after 
the addition of peaks B and C. Peak B induced a significant 
increase in  the amount of [3H]thymidine incorporation into 
DNA at all time points that were tested between 14 and 36 h 
(data  not  shown),  Peak C inhibited [3H]thymidine incorpo- 
ration between 14 and 36 h and did not appear to merely 
cause a delay in [3H]thymidine incorporation. 
To further characterize potential differences in the cellular 
response to  the peak B and peak C proteins, lZ5I-IGF-I binding 
was determined in  the presence of both forms of the binding 
protein. Addition of 100 ng/ml peak B to  the cultures for 14 
h prior to  and during the binding reaction resulted in a 72% 
increase in  IGF-I binding (Fig. 9). In  contrast,  addition of 25 
ng/ml peak C protein resulted in a 36% decrease in the 
amount of IGF-I that was  specifically bound. 
To determine whether the differences were due to differ- 
ences in the capacity of each form of the binding protein to 
adhere to cell surfaces, smooth muscle cell cultures were 
exposed to 50 ng/ml peak B binding protein for 14 h at 37 "C 
and  during the binding reaction. Following binding and affin- 
ity labeling, a  band was detected at 42 kDa (Fig. 10, lane B ) .  
lZ5I-IGF-I binding to this band was specific since it was 
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FIG. 4. A, HPLC of G-100 pool of peak  C IGF-I binding activity. 
One ml was injected on to a Vydac C-4, reverse-phase  column (4.6 
mm X 25 cm).  Sample was eluted isocratically  for 5 min  with 100% 
solvent A (0.04% trifluoroacetic  acid  in dH2O) followed by a linear 
gradient  to 100% solvent B (0.04% trifluoroacetic in  acetonitrile)  for 
25 minutes. The flow rate was 1.5 ml/min and absorbance was 
monitored at  214 nm. IGF-I binding activity (indicated by shaded 
area) eluted a t  51% solvent B. B, HPLC of DEAE-pool B IGF-I 
binding activity. 1.5 ml of DEAE-pool  B was injected on to a Vydac 
C-4, reverse-phase column (4.6 mm X 25 cm). Sample was eluted 
isocratically for 5 min with 100% solvent A, (0.04% trifluoroacetic 
acid and  H20) followed by a linear  gradient to 100% solvent B (0.04% 
trifluoroacetic  acid  in acetonitrile) for 25 min. The flow rate was 1.5 
ml/min and absorbance was monitored at  214 nm. IGF-I binding 
activity (indicated by shaded  area)  eluted a t  51% B. 
inhibited by excess unlabeled  IGF-I  but  not by  insulin. When 
peak C was added, no labeled band was detected  in  the 42- 
kDa region of the gel (lune E )  and binding to the type I 
receptor  appeared  to be  reduced. To  determine  whether  the 
differences in  the 42-kDa band  intensity were due  to differ- 
ences in the adherence properties of peaks B and C, we 
determined  the  capacity of radiolabeled forms of each  protein 
to  bind  to  smooth muscle cell cultures. The  addition of radi- 
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FIG. 5.  Analysis of purity of peak C IGF-I binding  protein 
at each step of purification. Samples were analyzed  for purity  on 
a 12% SDS-polyacrylamide gel. The experimental conditions are 
described under  “Experimental Procedures.” Ten pg of total protein 
that was present after each chromatographic step was loaded per 
lane. Lane A ,  crude  amniotic fluid; lane B, phenyl-Sepharose  chro- 
matography; lune C, peak  B after DEAE-cellulose chromatography; 
lune D, peak  C after DEAE-cellulose chromatography; lane E, peak 
C further purified by reverse-phase HPLC C-4 column; lane F, peak 
C further purified by G-100 and HPLC. BSA (69,000), ovalbumin 
(43,000), and myoglobin (18,500) were run  as  standards  as indicated. 
Silver staining was performed as described under “Experimental 
Procedures.” 
olabeled peak B resulted  in 8% of the  total  counts  per  minute 
added being specifically bound  to  the cell surface, whereas 
incubation  with  an  equal  amount of peak C showed no specific 
binding (Fig. 11). Addition of 50 ng/ml  non-radiolabeled  peak 
B resulted in significant  competition,  whereas an equal 
amount of peak C showed no competition. 
DISCUSSION 
The  insulin-like growth factor  binding  proteins  are known 
to circulate  in blood and  to be present  in  extracellular fluids. 
The extracellular fluid form(s) of the protein are usually 
unsaturated;  therefore,  they  have  the  potential  to bind  free 
IGF-I  and IGF-11. It  has been assumed  that  this large pool of 
carrier  protein  can  act as a storage reservoir for  IGF-I  and 
that  bound  IGF-I  is  in  an inactive form. These  studies dem- 
onstrate  that  this model is too simplistic. The  results show 
that human amniotic fluid contains two forms of the IGF 
binding  protein  that  have  similar physiochemical  properties 
but differ in  their  capacity  to  bind  to cell surfaces and in their 
capacity  to  enhance  the cellular  DNA synthesis response to 
IGF-I. Following separation  on DEAE-cellulose the two pro- 
teins were purified to homogeneity and the homogeneous 
preparations had markedly different biologic actions. The 
peak B form of the  binding  protein  potentiates  smooth muscle 
cell DNA synthesis 4.4-fold above the rate that can be 
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FIG. 6. Molecular weight estimate of peaks B and C by SDS- 
PAGE. Ten pg of peaks B and C were loaded on to a 12% SDS- 
polyacrylamide gel and the proteins separated under nonreducing 
conditions as described. The gel was stained as described previously. 
For isoelectric focusing of peaks B and C, 2.5 pg  of each protein were 
separated  on  precast isoelectric focusing plates as described under 
"Experimental Procedures." The gel was stained with Serva Blue or 
cut  into 0.5-cm slices and eluted with 0.04% trifluoroacetic acid. IGF 
binding activity of the eluates was determined and was detected in 
the slice corresponding to  the stained protein. 
achieved with IGF-I and PPP alone (26). This result is not 
accounted for by a contaminant since contaminants composed 
less than 0.5% of the sample and  the addition of the peak B 
protein  without  IGF-I or in  the presence of insulin has no 
stimulatory activity (26). In  contrast,  the peak C form of the 
protein  inhibited the effect of IGF-I  alone or the combined 
stimulatory effect of peak B  plus IGF-I. Therefore, the peak 
C form appears to be able to negate the effect that  the peak 
B form exerts  on  IGF-I  action. These effects are not due to 
changes in cell  cycle kinetics since addition of peak B did not 
alter  the time course of DNA synthesis by smooth muscle 
cells. Likewise, peak C did not simply delay the onset of [3H] 
thymidine incorporation by a mechanism similar to  the effect 
of transforming growth factor-@ on ARK-2B cells (27). Since 
the  net effect of the two proteins  appears to determine the 
cellular response to IGF-I, it  will  be important  to determine 
the relative abundance of these two forms in extracellular 
fluids. 
In contrast to these findings, several investigators have 
reported that partially purified preparations of IGF binding 
protein  inhibit  either the insulin-like (28) or growth-promot- 
ing actions (29) of IGF-I. Furthefiore,' one group used a 
homogeneous preparation of the  rat MSA binding protein and 
TABLE I1 
Amino acid composition of the IGF-I binding  protein 
Amino acid Peak B Peak C 
mol '% 
Aspartic acid and asparagine 7.3  7.6 
Glutamic acid and glutamine 15.1  14.9 
Serine 8.5  8.7 
Glycine 9.0  7.7 
Histidine 2.1 2.1 
Arginine 4.9 4.6 
Threonine 3.8 4.5 
Alanine 12.4 11.1 
Proline 8.0 8.8 
Tyrosine 2.8  2.5 
Valine 3.8 3.8 
Methionine 0.7  0.6 
Cysteine 4.4"  5.6" 
Isoleucine 3.6 3.9 
Leucine 8.1 8.2 
Phenylalanine 2.0 1.7 
Lysine 3.7 3.8 
Tryptophanb 
a Based on recovery of cysteine standard following hydrolysis. 
Tryptophan  is not detectable following hydrolysis. 
showed that  it blocked the DNA synthesis response of chick 
embryo fibroblasts to MSA (10). Since many of the purifica- 
tion schemes that were used to purify these proteins did not 
include DEAE-cellulose chromatography it is possible that 
these  partially purified preparations  contained both  the peak 
B and C forms of the binding protein. Since peak C is capable 
of inhibiting the cellular response to peak B plus IGF-I, failure 
to  separate  these two forms during purification could lead to 
these results. I t  is also possible that species differences could 
account for these discrepancies since the  rat homologue of the 
extracellular  binding  protein has a different N-terminal se- 
quence (30) and therefore it might not be capable of eliciting 
the same biologic response. 
The exact molecular property that accounts for the differ- 
ences in the cellular response to peaks B and C was not 
identified. Although we found that  the two components had 
slightly different  elution profiles from DEAE-cellulose, they 
had nearly identical isoelectric point determinations. This 
discrepancy could be due to preferential association of the 
peak B form of the protein with other proteins that elute at  
lower salt concentrations.  A second possibility is that peak B 
aggregates into multimeric forms during the ion exchange 
step  as a  result of concentration and  that such aggregation 
alters  the exposed charge groups but  that aggregation does 
not occur during isoelectric focusing. In addition,  both forms 
had identical molecular weight estimates, very similar amino 
acid compositions, and identical N-terminal sequences, and 
both  had  no detectable carbohydrate content by Schiff s stain- 
ing. The binding  affinity  estimates of each form of the protein 
for IGF-I showed complex kinetics that were consistent  with 
a  two-site model of competition for each form, but  the affinity 
estimates for each form were not substantially different. The 
affinity of these  proteins for IGF-I1 was not  determined and, 
therefore, we cannot directly compare our binding results to 
those of Binoux et al. (15) who found two binding proteins 
with different affinities for IGF-I and IGF-I1 in a crude 
preparation of human  spinal fluid. 
A major difference in the membrane adherence  properties 
of these two proteins was noted. Direct  measurements of the 
binding of radiodinated forms of each protein showed that 
peak B attached  to  the cell surfaces, whereas peak C did not. 
Likewise, non-radiolabeled peak B was shown to  both  adhere 
to smooth muscle cell surfaces and to increase the total 
amount of '251-IGF-I that was bound. In contrast,  non-radio- 
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FIG. 7. Scatchard plots of IGF-I binding to the  peaks B and 
C proteins. lZ5I-IGF-I (0.27 ng/ml) and increasing concentrations of 
unlabeled  IGF-I were incubated  with 14 ng/ml of either peak B (A) 
or peak C (0) binding  protein. Following a 48-h incubation at  4 “C 
the bound and free  lZ5I-IGF-I were separated by immunoprecipitation 
as described under “Experimental Procedures.” 83% of the total 
bound  IGF-I was precipitated under  the conditions used. 
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FIG. 8. Effects of peak B and C IGF-binding proteins on 
IGF-I-stimulated DNA synthesis. Quiescent  porcine  smooth  mus- 
cle cell cultures were exposed to a  basal medium containing 0.2 ml 
DMEM  and 1% PPP. Additional cultures received 20 ng/ml IGF-I or 
10 pg/ml insulin. Other  cultures were exposed to pure peak B or C 
with or without IGF-I. After a  36-h  incubation  [3H]thymidine  incor- 
poration into DNA was determined. The values plotted are  the  means 
of triplicate  determinations. 
labeled peak C did not  attach  to cell surfaces and exposure of 
cells to peak C did not result  in an enhancement of lZ5I-IGF- 
I binding. Since peak C inhibits  the DNA synthesis response 
to IGF-I, it is possible that  the presence of peak C in the 
incubation medium competitively inhibits lz5I-IGF binding, 
and thereby reduces the  amount of IGF-I that is available to 
attach  to  the type  I  IGF receptor. These findings also suggest 
that  attachment of peak B to  the cell surface and  the subse- 
quent increase in  IGF-I binding that is detected are linked to 
L *trot 2: P 
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FIG. 9. Alteration in ”“I-IGF binding induced by cell ex- 
posure to the IGF binding proteins. Porcine aortic smooth muscle 
cell cultures were incubated with peak B or peak C for 14  h at  37 “C.  
At that time the cultures were washed and fresh peak B or C added 
with 1251-IGF-I (1.0 ng/ml) and  the binding  reaction  carried out for 2 
h a t  8 “C.  The cultures were washed four times with PBS  and  the 
cell-associated ’T-IGF-I was determined as described under “Exper- 
imental Procedures.” 







FIG. 10. Affinity labeling of cell-associated binding protein 
with lZ6I-IGF-I. Pure IGF binding protein, peaks B and C, were 
incubated with smooth muscle cells. The monolayers were then 
washed and ’2sI-IGF-I (2.0 ng/ml) added. After a 2-h incubation at  
8 “C,  affinity labeling was performed as described under  “Experimen- 
tal Procedures.” The labeled proteins were solubilized and separated 
by 10% SDS-PAGE. The autoradiographs show the following: lane 
A ,  control,  no  addition; lane B, peak B (50 ng/ml); lane C, peak B + 
unlabeled IGF-I (50 ng/ml); lane D, peak B + insulin (10 pglml); lane 
E ,  peak C (50 ng/ml). 
14210 Purification  of a Human  Amniotic Fluid Protein 
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FIG. 11. Binding of '261-IGF binding proteins to smooth 
muscle cell monolayers. Confluent smooth muscle cell monolayers 
(76,000 cells/cm2) were exposed to lZ61-IGF binding protein peak B 
(open boxes) or peak C (hatched boxes), 80,000 cpm in 0.5 ml of 
binding medium (as described under "Experimental Procedures"). 
After  a 2-h incubation at 4 "C the  cells were washed three times with 
PBS and the cell-associated radioactivity was determined. Duplicate 
wells contained increasing concentrations of each form of unlabeled 
IGF binding protein. The results are expressed as  the mean & 1 S.D. 
of triplicate determinations. 
potentiation of the DNA synthesis response. Since at present 
this difference in  the membrane adherence of these two forms 
of IGF binding protein is the only identifiable distinctive 
feature that has been linked to  the differences in the cellular 
DNA synthesis response, it is critical to determine how this 
increase in  the amount of IGF-I that  is bound affects the type 
I receptor signaling mechanism. Potential binding protein- 
type  I receptor interactions that might be modified  by adher- 
ence of the IGF-I-binding protein complex to cell surfaces 
and subsequently enhance the transmembrane mitogenic sig- 
naling would include acceleration of receptor clustering, re- 
tardation of the  rate of type I receptor internalization, block- 
ing IGF-I degradation, and a change in receptor confirmation 
that results  in  enhanced affinity for IGF-I or direct binding 
of the IGF-I-binding protein complex to  the receptor to a  site 
that is distinct from the  IGF-I binding site. Direct evidence 
supporting one of these mechanisms is  not available, but since 
the IGF-I mitogenic signal is believed to be type I receptor- 
mediated each of these potential mechanisms is worthy of 
consideration. 
The  structural difference between peak B and C that ac- 
counts for the differences in membrane adherence and bio- 
logic response was not identified. Although the amino acid 
compositions were very similar and  the first 28 residues of 
each protein are identical, it is possible that there  are  other 
as yet unidentified minor sequence differences. Likewise, 
other  post-translational modifications such  as  fatty acid ad- 
dition (31), carboxylation (32), phosphorylation, or internal 
disulfide bond rearrangements have not been excluded. It is 
likely that one of these modifications exists and  that  it ac- 
counts for the observed differences in biologic activity. Addi- 
tion of fatty acids such as palmitate can account for the 
membrane adherence properties of proteins. Specifically, the 
P-21 RAS protein will not adhere to  the cytoplasmic surface 
of the plasma membrane unless palmitate has been added 
(33). Since the membrane adherence properties of the peak B 
binding protein correlate with its capacity to simulate DNA 
synthesis, it is possible that such  a modification could explain 
both of the observed differences between peaks B and C. 
Identification of this specific difference would be of major 
importance in  understanding the control of IGF-I action at 
the cell surface. 
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